Navigation Links
Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
Date:1/24/2008

LAVAL, QC, Jan. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS) today announced that it has entered into a licensing and distribution agreement with iNova Pharmaceuticals (Australia) Pty Limited for its once-daily tramadol product for Australia.

"Building on the launch of our once-daily tramadol product across Europe and in Canada, we continue to add strong distribution partners as we prepare for additional product launches in key markets globally throughout this year," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Australia represents a sizable opportunity and is an important component of the global commercialization plan for our product."

Under terms of the agreement, iNova will have the exclusive right to market and sell Labopharm's once-daily tramadol product in Australia. Labopharm will supply iNova with finished packaged product and will receive revenue from product sales commensurate with those of previous licensing and distribution agreements that Labopharm has entered into for European markets. Labopharm will also receive payments upon the achievement of certain milestones.

Labopharm is awaiting regulatory and pricing approval of its once-daily tramadol formulation in Australia, which is expected in the first half of 2008, with launch to occur thereafter.

About iNova Pharmaceuticals (Australia) Pty Limited

iNova Pharmaceuticals (Australia) Pty Limited develops and markets a range of over-the-counter and prescription medicines to Australasia, Asia-Pacific, South Africa and other international markets directly and also through other pharmaceutical companies and agents. The company works in partnership with sales and marketing partners and pharmaceutical companies in other countries to make their medicines available to the broader international community. iNova was borne out of more than 50 years heritage from Riker Laboratories and 3M Pharmaceuticals following t
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
11. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... LAKES, N.J., Nov. 21 To...edical intervention in treating 88 percent of pati... of Americans treated for a chronic condition acco...ng and 75 percent of all medical costs. A proprie... by Medco Health Solutions, Inc. (NYSE: MHS ) si...
(Date:11/21/2008)...nts in mice find running increases production of n...althDay News) -- In experiments in mice, exercise ...f brain stem cells usually seen with aging, Taiwan...ration of the brain,s ability to stave off aging a...a neurochemical that is essential for the producti...
(Date:11/21/2008)..., Nov. 21 /PRNewswire/ -- For the second year i..., McCann Healthcare Worldwide,s agency network wo...rk at the 22nd annual international RX Club Show. ...y offices won a total of 59 RX Club Awards of Exce...ng McCann Healthcare Worldwide agencies include Ca...
(Date:11/21/2008)...Nov. 21 Innerscope Research(TM), a...ializing in Emotional Response Measurement,annou... will strengthen the,company,s research and devel...es. , The three appointments, who deliver a...y Gill as Chief Financial Officer and Vice Preside...
Breaking Medicine News(10 mins):Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Exercise Keeps the Brain Young 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2
...orn to women with high levels of lead in their bon... babies exposed to lead from sources like old pain...the journal Pediatrics, they said this type of lea... health problem, in view of the long residence tim...
...t with medications can reduce abdominal fat in peo...rsity of Texas have been looking into the effect t...2 diabetes.// They studied 10 people with the cond... After this time body weight had, on the whole, in...
...ect people who are at high risk of suffering a str...is cheap enough to be used by opticians and GPs to...cell death due to bleeding from damaged blood vess...e in high-risk patients are available, so doctors ...
...tective substances, produced by the body in stress... TB bacteria, researchers in the UK report. Accord...ature Medicine,// these heat-shock proteins, which...cells survive stressful times and bolster the immu...
Other Medicine News:
(Date:11/20/2008)...ewswire/ -- Milk. It does a body good. And,now it...fter years of,research, scientists at OncoNutriti...lk that stimulate the body,s own production of ant...s Release, go to:, http://www.prnewswire.com/mnr/e...ew cancer therapies, the chief scientist, Dr. Davi...
(Date:11/20/2008)...-- Clinical data from a prospective,registry pres... shows DVT,treatment with the Trellis(R) Peripher...anta Clara, CA) successfully breaks up the blood c... This technique, called isolated pharmacomechanic... and safely than current catheter-directed thrombo...
(Date:11/19/2008)... Amgen,(Nasdaq: AMGN )...bsidiary of,Takeda Pharmaceutical Company Limited...the Phase 3 MONET1 trial evaluating motesanib (AMG...tin for the first-line treatment of,advanced non-...y suspended,following a planned safety data revie...
(Date:11/19/2008)...re/ -- Isogen, a contract development and,manufac...ounced the first,phase launch of its contract fac...ally address the process, facility and capacity pr...ghly-niched, low-volume clinical and,early-stage ... Companies can invest over $100 million and four ...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2BioMarin Announces First Quarter 2008 Financial Results 4955 1BioMarin Announces First Quarter 2008 Financial Results 4955 2BioMarin Announces First Quarter 2008 Financial Results 4955 3BioMarin Announces First Quarter 2008 Financial Results 4955 4BioMarin Announces First Quarter 2008 Financial Results 4955 5BioMarin Announces First Quarter 2008 Financial Results 4955 6BioMarin Announces First Quarter 2008 Financial Results 4955 7BioMarin Announces First Quarter 2008 Financial Results 4955 8BioMarin Announces First Quarter 2008 Financial Results 4955 9BioMarin Announces First Quarter 2008 Financial Results 4955 10BioMarin Announces First Quarter 2008 Financial Results 4955 11Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 1Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 2Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 3Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 4Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 1Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 2Engineers harness cell phone technology for use in medical imaging 4950 1Engineers harness cell phone technology for use in medical imaging 4950 2Engineers harness cell phone technology for use in medical imaging 4950 3Engineers harness cell phone technology for use in medical imaging 4950 4
...PHIS, Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, ...m the recent Phase II proof of,concept clinical tr... clinical trial evaluating ACAPODENE(R) (toremifen...e effects of androgen,deprivation therapy (ADT) wi...g of the American Society of Clinical Oncology bei...
...NFORD, Calif.--(BUSINESS WIRE)--May 24, 2007 - A n...studies are designed in ways,that inadvertently om... The Stanford University School of Medicine,resear...emind all,scientists that strict study eligibility...es., In reviewing data from a pool of 100,000 alco...
Other Medicine Technology:GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 2Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 3
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband.
A rapid rise in intracranial pressure requires early recognition, intervention and continuous monitoring. Ventrix utilizes state-of-the-art fiberoptic technology that gets to the source of pressure.
The Codman ICP Monitoring System provides highly accurate measurements of intracranial pressure at the source-subdural, parenchymal or intraventricular levels. The information is relayed electronical
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)
Medicine Products: